Biologics/Update·FDA Vaccines, Blood & Biologics

510(k) Blood Establishment Computer Software - 2026

MediumPublished Jun 10, 2026· AI-analyzed Jun 10, 2026View original FDA source

AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.

What happened

The FDA has published the 2026 listing of 510(k) clearances for Blood Establishment Computer Software (BECS).

Who it affects

This notice affects manufacturers of BECS, software developers in the biologics space, and blood banking establishments that utilize cleared software for operations.

Why it matters

As BECS is a critical component in ensuring the safety and efficacy of the blood supply, these clearances reflect the current regulatory status of market-available software products. For compliance professionals, this list serves as a formal record of authorized software, which is essential for vendor qualification and maintaining the validated state of blood establishment operations. The publication of this list suggests continued FDA oversight of digital infrastructure within the biologics sector.

Practical takeaway

Regulatory teams should monitor this list regularly to verify the clearance status of competitive products and ensure their own BECS 510(k) submissions are correctly recorded in the public registry. Manufacturers should also review these listings to identify the predicate devices currently being cited in the 2026 landscape.

FDA source material

Listing of 510(k) Blood Establishment Computer Software for the year 2026

Open in openFDA / FDA.gov

AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.

510(k) Blood Establishment Computer Software - 2026

More from Biologics